APPILI THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 CAD | 0.00% |
|
+14.29% | +14.29% |
| Apr. 02 | Appili Therapeutics To be Acquired by Aditxt, Inc. | MT |
| Apr. 02 | Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Companyâs anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.
Calendar
2024-06-25
- Q4 2024 Earnings Release (Projected)
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 3.53M | |
| -0.14% | 103B | |
| +3.45% | 96.73B | |
| +1.66% | 21.31B | |
| -15.50% | 21.21B | |
| -6.54% | 18.79B | |
| -41.41% | 16.37B | |
| -22.41% | 13.68B | |
| +6.81% | 13.44B | |
| +24.11% | 10.98B |
- Stock Market
- Equities
- APLI Stock
- News Appili Therapeutics Inc.
- Appili Therapeutics : Says First Patient Dosed in Phase 3 Clinical Trial of Tablets For Treatment of COVID-19 in the U.S.
